(200k) Production of Anti-CD20 Monoclonal Antibody Biosimilar

The monoclonal antibodies (mAbs) targeting CD20, such as ofatumumab and obinutuzumab, have been successfully applied to treat chronic lymphocytic leukemia. The development of biosimilar anti-CD20 mAb with improved production efficiency and reduced production cost is very important. In this study, CHO DG44/anti-CD20 mAb production cell line was developed using dhfr deficient expression system after serial selection and single cell cloning. The top three clones produced mAb with titer 200 mg/L in batch culture, while a high mAb titer of 2,000 mg/L was achieved in fed-batch culture using stirred-tank bioreactor. The purified mAb showed strong and specific binding and efficient toxicity to cancer cells with CD20 expression.